Advanced search
Publication Cover
RNA Biology Volume 19, 2022 - Issue 1
Submit an article Journal homepage
2,123
Views
1
CrossRef citations to date
0
Altmetric
Research Paper

Background splicing as a predictor of aberrant splicing in genetic disease

D. Alexievaa Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College London, London, UKView further author information
,
Y. Longa Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College London, London, UKView further author information
,
R. Sarkara Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College London, London, UKView further author information
,
H. Dhayana Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College London, London, UKView further author information
,
E. Brueta Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College London, London, UKView further author information
,
R. M. Winstona Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College London, London, UKView further author information
,
I. Vorechovskyb Faculty of Medicine, University of Southampton, Southampton, UKORCID Iconhttps://orcid.org/0000-0002-6740-6502View further author information
ORCID Icon,
L. Castellanoc Department of Surgery and Cancer, Imperial College London, Imperial Centre for Translational and Experimental Medicine (Ictem), London, UK;d School of Life Sciences, University of Sussex, Falmer, UKORCID Iconhttps://orcid.org/0000-0002-3059-4829View further author information
ORCID Icon &
N. J. Dibba Department of Metabolism, Digestion and Reproduction, Institute of Reproductive and Developmental Biology, Imperial College London, London, UKCorrespondence[email protected]
View further author information
 show all
Pages 256-265 | Received 27 May 2021, Accepted 26 Dec 2021, Published online: 19 Feb 2022

References

  • Scotti MM, Swanson MS. RNA mis-splicing in disease. Nat Rev Genet. 2016;17(1):19–32.
  • Baralle D, Buratti E. RNA splicing in human disease and in the clinic. Clin Sci (Lond). 2017;131(5):355–368.
  • Jian X, Boerwinkle E, Liu X. In silico tools for splicing defect prediction: a survey from the viewpoint of end users. Genet Med. 2014;16(7):497–503.
  • Moles-Fernandez A, Duran-Lozano L, Montalban G, et al. Computational tools for splicing defect prediction in breast/ovarian cancer genes: how efficient are they at Predicting RNA Alterations? Front Genet. 2018;9:366.
  • Alvarez MEV, Chivers M, Borovska I, et al. Transposon clusters as substrates for aberrant splice-site activation. RNA Biol. 2021;18(3):354–367.
  • Buratti E, Chivers M, Hwang G, et al. DBASS3 and DBASS5: databases of aberrant 3’- and 5’-splice sites. Nucleic Acids Res. 2011;39:D86–91.
  • Kapustin Y, Chan E, Sarkar R, et al. Cryptic splice sites and split genes. Nucleic Acids Res. 2011;39(14):5837–5844.
  • Pickrell JK, Pai AA, Gilad Y, et al. Noisy splicing drives mRNA isoform diversity in human cells. PLoS Genet. 2010;6(12):e1001236.
  • Wilks C, Gaddipati P, Nellore A, et al. Snaptron: querying splicing patterns across tens of thousands of RNA-seq samples. Bioinformatics. 2018;34(1):114–116.
  • Divina P, Kvitkovicova A, Buratti E, et al. Ab initio prediction of mutation-induced cryptic splice-site activation and exon skipping. Eur J Hum Genet. 2009;17(6):759–765.
  • Stenson PD, Mort M, Ball EV, et al. The human gene mutation database (HGMD((R))): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139(10):1197–1207.
  • Fokkema IF, Taschner PE, Schaafsma GC, et al. LOVD v.2.0: the next generation in gene variant databases. Hum Mutat. 2011;32(5):557–563.
  • Kent WJ. BLAT–the BLAST-like alignment tool. Genome Res. 2002;12(4):656–664.
  • Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006.
  • Thomassen M, Blanco A, Montagna M, et al. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat. 2012;132(3):1009–1023.
  • Whiley PJ, de La Hoya M, Thomassen M, et al. Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. Clin Chem. 2014;60(2):341–352.
  • Wappenschmidt B, Becker AA, Hauke J, et al. Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction. PLoS One. 2012;7(12):e50800.
  • Colombo M, De Vecchi G, Caleca L, et al. Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations. PLoS One. 2013;8(2):e57173.
  • Baert A, Depuydt J, Van Maerken T, et al. Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. Oncol Rep. 2017;37(3):1379–1386.
  • Scholl T, Pyne MT, Russo D, et al. BRCA1 IVS16+6T–>C is a deleterious mutation that creates an aberrant transcript by activating a cryptic splice donor site. Am J Med Genet. 1999;85(2):113–116.
  • Di Blasi C, Jarre L, Blasevich F, et al. Danon disease: a novel LAMP2 mutation affecting the pre-mRNA splicing and causing aberrant transcripts and partial protein expression. Neuromuscul Disord. 2008;18(12):962–966.
  • Keegan NP. Pseudoexons of the DMD Gene. J Neuromuscul Dis. 2020;7(2):77–95.
  • Spurdle AB, Couch FJ, Hogervorst FB, et al., Group IUGVW. Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat. 2008;29(11):1304–1313.
  • Ohno K, Takeda JI, Masuda A. Rules and tools to predict the splicing effects of exonic and intronic mutations. Wiley Interdiscip Rev RNA. 2018;9(1). DOI:10.1002/wrna.1451
  • Sibley CR, Emmett W, Blazquez L, et al. Recursive splicing in long vertebrate genes. Nature. 2015;521(7552):371–375.
  • Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–69.
  • Darman RB, Seiler M, Agrawal AA, et al. Cancer-Associated SF3B1 hotspot mutations Induce cryptic 3′ splice site selection through use of a different branch point. Cell Rep. 2015;13(5):1033–1045.
  • DeBoever C, Ghia EM, Shepard PJ, et al. Transcriptome sequencing reveals potential mechanism of cryptic 3’ splice site selection in SF3B1-mutated cancers. PLoS Comput Biol. 2015;11(3):e1004105.
  • Ilagan JO, Ramakrishnan A, Hayes B, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25(1):14–26.
  • Zhang J, Lieu YK, Ali AM, et al. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci U S A. 2015;112(34):E4726–34.
  • Suzuki H, Kumar SA, Shuai S, et al. Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. Nature. 2019;574(7780):707–711.
  • Escobar-Hoyos L, Knorr K, Abdel-Wahab O. Aberrant RNA splicing in cancer. Annu Rev Canc Biol. 2019;3(1):167–185.
  • David JK, Maden SK, Weeder BR, et al. Putatively cancer-specific exon-exon junctions are shared across patients and present in developmental and other non-cancer cells. NAR Cancer. 2020;2(1):zcaa001.
  • Kim E, Ilagan JO, Liang Y, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015;27(5):617–630.
  • Inoue D, Chew GL, Liu B, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574(7778):432–436.
  • Inoue D, Bradley RK, Abdel-Wahab O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev. 2016;30(9):989–1001.
  • Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A. 1993;90(18):8673–8677.
  • Hu Y, Mohassel P, Donkervoort S, et al. Identification of a novel deep intronic mutation in CAPN3 presenting a promising target for therapeutic splice modulation. J Neuromuscul Dis. 2019;6(4):475–483.
  • Oustric V, Manceau H, Ducamp S, et al. Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria. Am J Hum Genet. 2014;94(4):611–617.
  • Uchikawa H, Fujii K, Kohno Y, et al. U7 snRNA-mediated correction of aberrant splicing caused by activation of cryptic splice sites. J Hum Genet. 2007;52(11):891–897.
  • Aartsma-Rus A, De Winter CL, Janson AA, et al. Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides. 2005;15(4):284–297.
  • Wilton SD, Fall AM, Harding PL, et al. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther. 2007;15(7):1288–1296.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.